New Product - Kalydeco
Kalydeco (ivacaftor) is a selective potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In vitro ivacaftor increases CFTR channel gating to enhance chloride transport. Kalydeco is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D or other gating (class III) mutation in the CFTR gene. It is available as a 150 mg tablet in packs of 56's.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629